A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors

This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors. The study will also identify the recommended dose for future studies. The trial includes two phases and is expected to last about 4 years, with treatment and follow-up lasting approximately 6-12 months each.

Trial Details

NCT ID
NCT07623369
Phase
PHASE1
Sponsor
Huahui Health
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • HH160
Locations (sample)
  • Waratah, New South Wales, Australia|-32.90667,151.72647
  • Southport, Queensland, Australia|-27.96724,153.39796
  • Jinan, Shandong, China|36.66833,116.99722

Key Eligibility Criteria

  • Adults aged 18 to 75 years with signed informed consent.
  • Histologically or cytologically confirmed advanced solid tumors meeting phase-specific disease requirements.
  • At least 1 measurable lesion per RECIST v1.1.
  • Eastern Cooperative Oncology Group Performance Status (ECOG) Performance Status of 0 or 1 with life expectancy ≥ 12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →